Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

SSP Q3 sales up despite turbulence in Germany, Asia and North America

(Sharecast News) - Bar and restaurant operator SSP said on Tuesday that group sales in Q3 were up 6% year-on-year in Q3 at constant currency rates despite seeing sales momentum soften mid-quarter. Like-for-like sales rose 3%, while contract gains added 4% and acquisitions chipped in 1%, though exits in Germany and India shaved off 2%.

Sales momentum softened halfway through the quarter, dipping from 5% like-for-like growth early on, boosted by Easter timing, to just 1% over the final seven weeks, impacted by a weaker performance in the UK and Asia. With that said, SSP noted that trading picked up again in early Q4, with LFL growth around 3%.

North American sales rose 5%, though LFL sales slid 2% amid lower passenger volumes as geopolitical jitters weighed on travel, while sales in Continental Europe were broadly flat. UK sales climbed 7%, buoyed by Easter and early strength, although M&S cyber issues disrupted mid-quarter trading. APAC and EEME surged 16%, driven by strong passenger flows in Malaysia, Egypt and Australia.

For the nine months ended 30 June, SSP said group revenues had risen 10% at constant currency, with solid gains across contracts and M&A offsetting some regional pressures.

Looking forward, SSP said it would accelerate cost-cutting and efficiency drives in an effort to support margins and returns, and noted that it remains on track to hit FY targets, currency headwinds notwithstanding.

As of 0805 BST, SSP shares were down 0.28% at 177.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.